Draft:Genomics (company)
 | Review waiting, please be patient.
This may take 4 weeks or more, since drafts are reviewed in no specific order. There are 517 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 16 June 2025 by KylieTastic (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
| Submission declined on 11 June 2025 by GoldRomean (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission reads more like an essay than an encyclopedia article. Submissions should summarise information in secondary, reliable sources and not contain opinions or original research. Please write about the topic from a neutral point of view in an encyclopedic manner. Declined by GoldRomean 11 days ago. | |
| Submission declined on 10 June 2025 by Protobowladdict (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject. Declined by Protobowladdict 11 days ago. | |
| Company type | Private |
|---|---|
| Industry | Biotechnology, Genomics |
| Founded | 2014 |
| Founders | Peter Donnelly, Gil McVean, Gerton Lunter, Chris Spencer |
Key people | Sir Peter Donnelly (CEO) (2025)
David Thornton (President) |
| Products | Polygenic risk scoring, Target discovery |
| Website | www.genomics.com |
Genomics (legally Genomics Ltd, formerly known as Genomics plc) is a British biotechnology company founded in 2014 as a spin-out from the University of Oxford. It develops genomic analytics tools for disease risk prediction and drug discovery. Sir Peter Donnelly, co-founder and Emeritus Professor of Statistical Science at Oxford, has served as its Chief Executive Officer since its founding.[1][2]
History
[edit]Genomics was established in 2014 by Peter Donnelly, Gil McVean, Gerton Lunter, and Chris Spencer.[2] In 2018, the company raised £25 million, including a £10.5 million investment from Vertex Pharmaceuticals, and launched a three- to five-year drug target discovery collaboration. This partnership was extended in 2021 and again in 2024, now continuing through 2026.[3][4]
Technology
[edit]The company operates a proprietary database that connects genetic variants at over 14 million genome positions with clinical traits and outcomes. Using machine learning, it generates polygenic risk scores (PRS) to estimate individuals’ genetic susceptibility to diseases such as cancer, heart disease, and diabetes.[5] These risk scores support precision health by identifying individuals for early screening or intervention and aid pharmaceutical R&D through genetic target validation.[5][6]
Partnerships
[edit]Genomics maintains a longstanding research partnership with Vertex Pharmaceuticals, focused on integrating human genetics and data science into drug discovery.[3] In public health, it collaborates with the UK government-backed Our Future Health program to apply PRS at scale.[7] The company also works with insurers such as MassMutual and pharmaceutical firms including GSK to integrate genetic risk tools into clinical trials and healthcare systems.[6][8][9]
References
[edit]- ^ "Bupa to offer first genetic test for disease prediction in UK".
- ^ a b "Genomics PLC company profile: funding, investors & partnerships".
- ^ a b "Genomics PLC Extends Partnership with Vertex Pharmaceuticals".
- ^ "Vertex and Genomics expand collaboration to accelerate precision medicines".
- ^ a b "Polygenic risk predictions" (PDF).
- ^ a b "Gene screening can cut early disease deaths by 25%, study shows".
- ^ "Genomics plc announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches".
- ^ "MassMutual Expands Voluntary Genetic Testing Program".
- ^ "Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design".
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.